BioSpace News Archive

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 6, 2021.

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced its participation in the following conferences in May.

Advanced Human Imaging Limited is pleased to announce that, further to the April 19, 2021 letter of intent announcement, it has executed a Binding Heads of Agreement for the proposed acquisition of Israeli based musculoskeletal assessment company Physimax Technologies Limited.

Soliton, Inc., a medical device company with a novel and proprietary platform technology, announced the U.S. Food and Drug Administration clearance of the Company’s special 510 for modifications to its RESONIC™ device.

Research fellows were recognized for their excellence in basic and clinical research at the annual National Young Investigators Forum on April 22 and April 23.

Independent data safety monitoring board (DSMB) formally recommends investigational combination therapy advance to Phase 3 following Phase 2 pre-specified analysis for safety and efficacy

Financing led by RA Capital Management with participation from Perceptive Advisors, Surveyor Capital (a Citadel company), Octagon Capital, Marshall Wace, and Drive Capital Proceeds to accelerate the expansion of the contract development and manufacturing organization (CDMO) capacity for production of cGMP adeno-associated viruses (AAV)

Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021.

- Novel mechanism of action, highly differentiated safety profile, 2000+ subjects studied in 27 clinical trials across Europe and US; FDA Fast Track status granted - NCE has potential to addresses significantly under-served market comprising acute and chronic pain, central and peripheral neuropathy, cancer pain, and addiction treatment

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced new data to be presented at the upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy